1. Overview
Gliadin is a protein component of gluten, which is found primarily in wheat. Gliadin antibodies (Anti-Gliadin Antibodies, AGA) are produced by the immune system in response to gliadin exposure and play a role in the screening and evaluation of celiac disease and related gluten-sensitive disorders.
These antibodies target gliadin-derived peptides, which are the major antigenic components of gluten. Gliadin is encoded by three different alleles (AA, BB, and DD).
Although antigliadin antibodies were historically used for celiac disease screening, their diagnostic value has declined with the advent of more specific markers such as tissue transglutaminase (tTG) antibodies. However, the use of synthetic or deamidated gliadin peptides (DGP) in ELISA testing has significantly improved sensitivity and specificity, particularly in young children under 5 years of age.
In patients with IgA deficiency, AGA IgG remains an important and sometimes the only positive serological marker.
2. Symptoms
Gliadin antibodies themselves do not cause symptoms; rather, clinical manifestations arise from underlying gluten-related disorders.
Patients may present with symptoms of celiac disease, such as chronic diarrhea, abdominal pain, bloating, weight loss, malabsorption, and nutritional deficiencies. Extra-intestinal manifestations may include iron-deficiency anemia, fatigue, growth failure in children, and neurological symptoms such as cerebellar ataxia.
Cutaneous manifestations such as dermatitis herpetiformis, often described as the “celiac disease of the skin,” may also be associated with gliadin antibody positivity.
3. Causes
Gliadin antibody production results from an immune-mediated response to dietary gluten. In gluten-sensitive individuals, ingestion of gluten leads to intestinal inflammation, flattening of intestinal villi, and malabsorption, a condition known as gluten-sensitive enteropathy (celiac disease).
The immune response involves IgA-dominant autoimmunity against transglutaminase enzymes. In classical celiac disease, the main target is tissue transglutaminase, whereas in dermatitis herpetiformis, epidermal transglutaminase (TG3) is increasingly recognized as the dominant antigen.
Gliadin antibodies are not entirely specific to celiac disease and may also be detected in other gastrointestinal conditions such as gastritis, gastroenteritis, inflammatory bowel disease, and non-celiac gluten sensitivity.
4. Risk Factors
Risk factors for positive gliadin antibodies include genetic predisposition to celiac disease, family history of gluten-related disorders, and associated autoimmune conditions such as type 1 diabetes mellitus and autoimmune thyroid disease.
Children under 2 years of age benefit more from deamidated gliadin peptide antibody testing due to the limited sensitivity of tTG antibodies in this age group.
Patients with IgA deficiency represent a special risk group, as IgA-based tests may be falsely negative, making IgG-based gliadin antibody testing essential.
Gliadin antibodies may also be elevated in patients with malabsorption syndromes and non-celiac gluten sensitivity, requiring careful clinical correlation.
5. Prevention and Clinical Management
Gliadin antibody testing is primarily used for screening, supportive diagnosis, and disease monitoring, rather than prevention. Indications include suspected celiac disease, non-celiac gluten sensitivity, cerebellar ataxia, dermatitis herpetiformis, chronic malabsorption, unexplained iron-deficiency anemia, family history of celiac disease, and follow-up of diagnosed patients to assess dietary compliance.
Serum samples are collected from fasting patients, with 2–3 mL of blood drawn into a plain red-capped tube and stored at 2–8°C. Hemorrhagic, icteric, or grossly lipemic samples are unsuitable for analysis.
Laboratory estimation methods include ELISA, immunofluorescence assay (IFA), multiplex immunoassay, and immunoblot (Western blot).
IgA antigliadin antibodies are more sensitive and specific for celiac disease in individuals with normal IgA levels, as they reflect intestinal immune activity. IgG antigliadin antibodies are less specific but remain useful in IgA-deficient patients and as supportive markers in gluten-related disorders.
Reference ranges typically define <12 U/mL as negative for both IgA and IgG, with higher values suggesting gluten sensitivity or celiac disease. Deamidated gliadin peptide antibodies show improved diagnostic accuracy.
Limitations include lower specificity compared to tTG and endomysial antibodies, possible false positives in infections or autoimmune diseases, false negatives, and the need for a confirmatory intestinal biopsy for definitive diagnosis. Sensitivity and specificity are approximately 90%.
Overall, gliadin antibodies remain a valuable adjunctive tool in selected clinical settings, especially in young children, IgA-deficient patients, and in monitoring response to a gluten-free diet.
